undefined undefined
NaN.000
NaN.00%
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
05-16 18:50
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by 5.13 percent. This is a 78.97 percent increase over losses of $(1.95) per share from the
05-15 20:14
CervoMed (CRVO) has provided an announcement. CervoMed Inc. has made key detail...
04-23 20:13
加拿大投资银行集团:维持CervoMed(CRVO.US)评级,由买入调整至买入评级, 目标价由50.00美元调整至65.00美元。
04-08 19:40
CervoMed press release (NASDAQ:CRVO): FY GAAP EPS of -$0.82 beats by $1.23. Revenue of $7.14M beats by $3.09M. As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compar...
04-01 20:50
Gainers: Avalo Therapeutics (AVTX) +263%. iBio (IBIO) +35%. Mesoblast ADR (MESO) +20%. Universe Pharmaceuticals (UPC) +16%. CervoMed (CRVO) +22%. Losers: Kodiak Sciences (KOD) -20%. PAVmed (PAVM) -9%....
03-28 22:01
CervoMed (NASDAQ:CRVO) said on Thursday it had entered into a definitive securities purchase agreement for a private placement to sell ~2.5M units. Shares of CRVO jumped 18.8% in premarket trading. Ea...
03-28 21:12
CervoMed (CRVO) has issued an announcement. CervoMed Inc. has engaged in a $50 ...
03-28 20:52
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients
02-07 21:35
Oral neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health and slow or prevent disease progression, which would make it the first disease-modifying treatment ...
2023-10-18 19:00